Alkem Laboratories Limited has informed the Exchange regarding a revised press release dated November 03, 2025, titled "Alkem Foundation and IIT Bombay announce strategic collaboration to set up advanced research centre for immuno-therapeutics and regenerative medicines".
ALKEM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Alkem Foundation, the CSR arm of Alkem Laboratories, has announced a strategic collaboration with IIT Bombay to set up India's first dedicated research centre for immuno-therapeutics and regenerative medicines on the IIT Bombay campus. Alkem Foundation will fund the 'Alkem Centre for Advanced Research and Development of Applied Immuno-Therapeutics and Regenerative Medicines' by contributing 20-25% of its cumulative CSR obligations over seven years. The centre will focus on gene editing, biomaterials, cell and gene therapy, and will also serve as a training and incubation hub for clinician-scientists and biotech entrepreneurs. This is described as the first industry-academia collaboration in India initiated through the CSR route for advancing research in these therapy areas. The initiative aims to position India as a global leader in applied biotechnology and create affordable, high-impact healthcare solutions.
This is a CSR-funded research initiative rather than a commercial deal, so it is unlikely to have a material direct impact on Alkem's stock price or near-term financials. However, it strengthens Alkem's brand and long-term R&D pipeline visibility in high-growth areas like immuno-therapeutics and regenerative medicine, which could be viewed positively by investors focused on innovation.